排序方式: 共有33条查询结果,搜索用时 31 毫秒
1.
2.
3.
Bhattachary-Chatterjee M Nath Baral R Chatterjee SK Das R Zeytin H Chakraborty M Foon KA 《Cancer immunology, immunotherapy : CII》2000,49(3):133-141
Anti-idiotype (Id) vaccine therapy has been tested and shown to be effective, in several animal models, for triggering the
immune system to induce specific and protective immunity against bacterial, viral and parasitic infections. The administration
of anti-Id antibodies as surrogate tumor-associated antigens (TAA) also represents another potential application of the concept
of the Id network. Limited experience in human trials using anti-Id to stimulate immunity against tumors has shown promising
results. In this “counterpoint” article, we discuss our own findings showing the potential of anti-Id antibody vaccines to
be novel therapeutic approaches to various human cancers and also discuss where anti-Id vaccines may perform better than traditional
multiple-epitope antigen vaccines.
Received: 27 December 1999 / Accepted: 27 January 2000 相似文献
4.
Ishigami S Sandkvist M Tsui F Moore E Coleman TA Lawrence DA 《The Biochemical journal》2007,402(1):25-34
Ns (neuroserpin) is a member of the serpin (serine protease inhibitor) gene family that is primarily expressed within the central nervous system. Its principal target protease is tPA (tissue plasminogen activator), which is thought to contribute to synaptic plasticity and to be secreted in a stimulus-dependent manner. In the present study, we demonstrate in primary neuronal cultures that Ns co-localizes in LDCVs (large dense core vesicles) with the regulated secretory protein chromogranin B. We also show that Ns secretion is regulated and can be specifically induced 4-fold by secretagogue treatment. A novel 13-amino-acid sorting signal located at the C-terminus of Ns is identified that is both necessary and sufficient to target Ns to the regulated secretion pathway. Its deletion renders Ns no longer responsive to secretagogue stimulation, whereas PAI-Ns [Ns (neuroserpin)-PAI-1 (plasminogen activator inhibitor-1) chimaera appending the last 13 residues of Ns sequence to the C-terminus of PAI-1] shifts PAI-1 secretion into a regulated secretory pathway. 相似文献
5.
Mary T. Litzinger Kenneth A. Foon Helen Sabzevari Kwong-Yok Tsang Jeffrey Schlom Claudia Palena 《Cancer immunology, immunotherapy : CII》2009,58(6):955-965
In chronic lymphocytic leukemia (CLL), malignant B cells and nonmalignant T cells exhibit dysfunction. We previously demonstrated
that infection of CLL cells with modified vaccinia Ankara (MVA) expressing the costimulatory molecules B7-1, ICAM-1, and LFA-3
(designated TRICOM) increased expression of these costimulatory molecules on the surface of CLL cells and thus augmented their
antigen-presenting capability. Here, we evaluate the effect of MVA-TRICOM-modified CLL cells on T cells. Following incubation
with irradiated MVA-TRICOM-modified CLL cells, allogeneic and autologous CD4+ and CD8+ T cells expressed significantly higher levels of B7-1, ICAM-1, and LFA-3. We show that this increase was the result of physical
acquisition from the antigen-presenting cells (APCs), and that purified T cells that acquired costimulatory molecules from
MVA-TRICOM-modified CLL cells were able to stimulate the proliferation of untreated T cells. These results demonstrate for
the first time that T cells from CLL patients can acquire multiple costimulatory molecules from autologous CLL cells and can
then act as APCs themselves. Given the immunodeficiencies characteristic of CLL, enhancing the antigen-presenting function
of CLL cells and T cells simultaneously could be a distinct advantage in the effort to elicit antitumor immune responses.
Electronic supplementary material The online version of this article (doi:) contains supplementary material, which is available to authorized users. 相似文献
6.
Quantitative identification of teratoma tissues formed by human embryonic stem cells with TeratomEye
Steve Kah Weng Oh Pauline Chua Koh Lin Foon Emily Ng Angela Chin Andre Boon Hwa Choo Rajagopalan Srinivasan 《Biotechnology letters》2009,31(5):653-658
An automated vision system, TeratomEye, was developed for the identification of three representative tissue types: muscle,
gut and neural epithelia which are commonly found in teratomas formed from human embryonic stem cells. Muscle tissue, a common
structure was identified with an accuracy of 90.3% with high specificity and sensitivity greater than 90%. Gut epithelia were
identified with an accuracy of 87.5% with specificity and sensitivity greater than 80%. Neural epithelia which were the most
difficult structures to distinguish gave an accuracy of 47.6%. TeratomEye is therefore useful for the automated identification
of differentiated tissues in teratoma sections. 相似文献
7.
Gunaratne J Goh MX Swa HL Lee FY Sanford E Wong LM Hogue KA Blackstock WP Okumura K 《The Journal of biological chemistry》2011,286(20):18093-18103
The tumor suppressor PTEN (phosphatase and tensin homologue) negatively regulates the PI3K pathway through its lipid phosphatase activity and is one of the most commonly lost tumor suppressors in human cancers. Though the tumor suppressive function involves the lipid phosphatase-dependent and -independent activities of PTEN, the mechanism leading to the phosphatase-independent function of PTEN is understood poorly. Some PTEN mutants have lipid phosphatase activity but fail to suppress cell growth. Here, we use a cancer-associated mutant, G20E, to gain insight into the phosphatase-independent function of PTEN by investigating protein-protein interactions using MS-based stable isotope labeling by amino acids in cell culture (SILAC). A strategy named parallel affinity purification (PAP) and SILAC has been developed to prioritize interactors and to compare the interactions between wild-type and G20E PTEN. Clustering of the prioritized interactors acquired by the PAP-SILAC approach shows three distinct clusters: 1) wild-type-specific interactors, 2) interactors unique to the G20E mutant, and 3) proteins common to wild-type and mutant. These interactors are involved mainly in cell migration and apoptosis pathways. We further demonstrate that the wild-type-specific interactor, NUDTL16L1, is required for the regulatory function of wild-type PTEN in cell migration. These findings contribute to a better understanding of the mechanisms of the phosphatase-dependent and -independent functions of PTEN. 相似文献
8.
The BRCA1 tumor suppressor forms a heterodimer with the BARD1 protein, and the resulting complex functions as an E3 ubiquitin ligase that catalyzes the synthesis of polyubiquitin chains. In theory, polyubiquitination can occur by isopeptide bond formation at any of the seven lysine residues of ubiquitin. The isopeptide linkage of a polyubiquitin chain is a particularly important determinant of its cellular function, such that K48-linked chains commonly target proteins for proteasomal degradation, while K63 chains serve non-proteolytic roles in various signaling pathways. To determine the isopeptide linkage formed by BRCA1/BARD1-dependent polyubiquitination, we purified a full-length heterodimeric complex and compared its linkage specificity with that of E6-AP, an E3 ligase known to induce proteolysis of its cellular substrates. Using a comprehensive mutation analysis, we found that E6-AP catalyzes the synthesis of K48-linked polyubiquitin chains. In contrast, however, the BRCA1/BARD1 heterodimer directs polymerization of ubiquitin primarily through an unconventional linkage involving lysine residue K6. Although heterologous substrates of BRCA1/BARD1 are not known, BRCA1 autoubiquitination occurs principally by conjugation with K6-linked polymers. The ability of BRCA1/BARD1 to form K6-linked polyubiquitin chains suggests that it may impart unique cellular properties to its natural enzymatic substrates. 相似文献
9.
Murine monoclonal anti-idiotype antibody as a potential network antigen for human carcinoembryonic antigen. 总被引:5,自引:0,他引:5
M Bhattacharya-Chatterjee S Mukerjee W Biddle K A Foon H K?hler 《Journal of immunology (Baltimore, Md. : 1950)》1990,145(8):2758-2765
Carcinomas of the gastrointestinal tract are not curable by standard therapies. Thus, new therapeutic approaches for this disease are needed. This study proposes the use of anti-Id mAb as Ag substitutes to induce anti-tumor immunity in gastrointestinal cancer patients. Recently, we have generated and characterized one monoclonal anti-Id antibody, designated 3H1 (Ab2), which mimics biologically and antigenically a distinct and specific epitope of the 180,000 m.w. carcinoembryonic antigen (CEA) primarily expressed in high density by human pancreatic and colonic tumor cells. This epitope is unique to CEA and not present on other CEA-related lower m.w. members of the Ag family also found on normal tissues. The antigenic determinant as defined by the mAb 8019 (Ab1) against which the Ab2, 3H1 was raised, is absent on normal adult tissues by immunoperoxidase staining and haematopoietic cells including granulocytes by flow cytometry analysis. Anti-Id (Ab2) 3H1 induced CEA-specific antibodies in mice and rabbits. The immune sera from both mice and rabbits competed with Ab1 for binding to the colon carcinoma cell line LS174T and inhibited the binding of radioiodinated Ab1 to Ab2. This indicates that anti-anti-Id (Ab3) in mice and rabbits share idiotopes with Ab1 (8019). Furthermore, monoclonal Ab3 that bind to CEA have been generated from mice immunized with 3H1. The Ab3 (both polyclonal as well as monoclonal) immunoprecipitated the same 180,000 m.w. CEA as Ab1 (8019) by Western blotting analysis and showed almost identical immuno-staining patterns as Ab1 on colonic adenocarcinoma tissue sections from several patients. Collectively these data suggest that Ab2 3H1 could potentially be used clinically as a network Ag for immunotherapy of patients with CEA positive tumors. 相似文献
10.
James A. Knost Stephen A. Sherwin Paul G. Abrams Jeffrey J. Ochs Kenneth A. Foon Roxanne Williams Richard Tuttle Robert K. Oldham 《Cancer immunology, immunotherapy : CII》1983,15(2):144-148
Summary Highly purified human lymphoblastoid interferon (HLBI) derived from virus-stimulated Namalwa cells was administered by 6-h IV infusion or IM injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received doses escalating from 0.1 to 50×106 U for up to 5 weeks. Extensive monitoring for clinical effect, toxicity, and pharmacokinetics has revealed higher peak serum interferon levels and somewhat more pronounced systemic toxicity for the IV than for the IM route of administration. Objective evidence of tumor regression was observed in two patients receiving HLBI IV. 相似文献